Palvella Therapeutics Inc’s recent filing unveils that its Director JENKINS GEORGE M acquired Company’s shares for reported $51720.0 on Dec 18 ’24. In the deal valued at $12.93 per share,4,000 shares were bought. As a result of this transaction, JENKINS GEORGE M now holds 180,671 shares worth roughly $ 3.53 million.
Then, GERAGHTY JAMES A bought 1 shares, generating $1 in total proceeds. Upon buying the shares at $1.00, the Director now owns 1 shares.
Before that, ADAR1 Capital Management, LLC bought 3,000 shares. Palvella Therapeutics Inc shares valued at $47,647 were divested by the 10% Owner at a price of $15.88 per share. As a result of the transaction, ADAR1 Capital Management, LLC now holds 129,574 shares, worth roughly $2.53 million.
TD Cowen initiated its Palvella Therapeutics Inc [PVLA] rating to a Buy in a research note published on February 05, 2025; the price target was $44. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering PVLA with “an Overweight” recommendation on December 18, 2024. Robert W. Baird revised its rating on March 13, 2020. It rated PVLA as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of PVLA
On Friday, Palvella Therapeutics Inc [NASDAQ:PVLA] saw its stock fall -2.25% to $19.55. Over the last five days, the stock has gained 25.72%. Palvella Therapeutics Inc shares have risen nearly 62.92% since the year began. Nevertheless, the stocks have risen 57.26% over the past one year. While a 52-week high of $22.32 was reached on 02/14/25, a 52-week low of $6.20 was recorded on 01/02/25. SMA at 50 days reached $14.10, while 200 days put it at $14.01.
Levels Of Support And Resistance For PVLA Stock
The 24-hour chart illustrates a support level at 18.18, which if violated will result in even more drops to 16.81. On the upside, there is a resistance level at 20.96. A further resistance level may holdings at 22.37. The Relative Strength Index (RSI) on the 14-day chart is 79.40, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.60, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 17.02%. Stochastics %K at 91.86% indicates the stock is a selling.
How much short interest is there in Palvella Therapeutics Inc?
A steep rise in short interest was recorded in Palvella Therapeutics Inc stocks on 2025-01-31, dropping by 3077.0 shares to a total of 13312.0 shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 16389.0 shares. There was a decline of -23.11%, which implies that there is a negative sentiment for the stock.
